Welcome to the G.LA.R.E. lab !
Advancing Precision Oncology
through Innovation
The G.LA.R.E. laboratory (Giamas Translational Cancer Research Lab; GLARE.BIO) is dedicated to advancing precision oncology through the identification, characterisation, and therapeutic targeting of proteins/genes critical to cancer progression. By integrating cutting-edge molecular, cellular, and biochemical approaches with clinically validated models, the lab bridges fundamental biological insights to transformative clinical applications.
​
Our work ensures that discoveries not only illuminate cancer biology but also directly shape therapeutic development and diagnostic innovation, aligning with the urgent need for personalised cancer care.
Research Focus
Decoding Cancer Mechanisms and Pathways
At the core of our mission is unravelling the molecular drivers of tumorigenesis, metastasis, and therapeutic resistance. Leveraging state-of-the-art in vitro systems (e.g., 3D organoids, CRISPR-edited cell lines and high-throughput screening platforms) and in vivo models (e.g., patient-derived xenografts), alongside multi-omics analyses of patient specimens (genomics, proteomics, transcriptomics), we dissect dysregulated signalling pathways and protein networks.
This integrative strategy enables the discovery of novel biomarkers for early diagnosis and the development of targeted therapies tailored to individual molecular profiles.
Translational Impact
From discovery to clinical integration
Our dual emphasis on mechanistic discovery and clinical translation addresses critical unmet needs in oncology. By validating preclinical findings in patient-derived data and specimens, we accelerate the "bench-to-bedside" pipeline, delivering actionable strategies for therapeutic intervention. Collectively, the lab’s work fosters a precision medicine framework, aiming to improve patient outcomes while advancing global oncology research by paving the way for next-generation diagnostics and therapies.
